NCT05724797 is a Phase 1 clinical trial of NRS-033 in Healthy Volunteers, sponsored by Nirsum Labs.

Who is sponsoring NCT05724797?

NCT05724797 is sponsored by Nirsum Labs.

What drugs are being tested in NCT05724797?

Interventions in NCT05724797: NRS-033, Placebo.

What condition does NCT05724797 study?

NCT05724797 studies Healthy Volunteers.

Is NCT05724797 still recruiting?

NCT05724797 is currently completed. Last updated 8 December 2025.

Last reviewed 2025-12-08 · How we verify

NCT05724797

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single Ascending Dose Study of NRS 033 in Healthy Volunteers

Completed Phase 1 Last updated 8 December 2025

What this trial tests

Phase 1 trial testing NRS-033 in Healthy Volunteers in 24 participants. Completed in 4 December 2024.

Timeline

17 April 2023

Primary endpoint
4 December 2024

4 December 2024

Quick facts

Lead sponsor	Nirsum Labs
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	24
Start date	17 April 2023
Primary completion	4 December 2024
Estimated completion	4 December 2024
Sites	1 location across United States

Drugs / interventions tested

NRS-033 — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Nirsum Labs — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1, first in human, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy adult male and female subjects 18 to 55 years of age, inclusive.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05724797 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nirsum Labs
Last refreshed: 8 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05724797.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing